Workshop 8 EU Action on Pancreas Cancer

September 2016

Chair:Elke Anklam, Director of EC JRC Directorate F – Health, Consumers and Reference Materials, Belgium

Speakers:Núria Malats, CNIO Madrid, SpainRicardo Baptista-Leite, Member of Parliament, PortugalMatthias Reumann, IBM Research Zurich, SwitzerlandLada Leyens, Swissmedic, SwitzerlandAngela Brand, Maastricht University, The Netherlands

2 /20

ESF provides the COST Office

through a European Commission contractCOST is supported

by the EU Framework Programme

An integrated European platform for pancreas cancer research: from basic science to clinical and public health

interventions for a rare diseaseCOST Action (BM1204)

Chair: Núria Malats, MD, MPH, PhDSpanish National Cancer Research Centre (CNIO), Spain

(nmalats@cnio.es)

3 /20

>250 multidiciplinary members from: 22 EU countries5 EU gov & non-gov institutions3 Biotech companies (SME)1 Pharma company

The Action aims to unite groups across Europe interested in pancreas cancerresearch and provides an innovative and unique platform for collaborating andsharing information, ideas and experience

Grant Period – 14 December 2012 to 13 December 20161st Grant Period – 31 May 20142nd Grant Period – 1 June 2015 3rd Grant Period – 1 May 2016

An integrated European platform for pancreas cancer research: from basic science to clinical and public health interventions

for a rare disease COST Action (BM1204)

www.eupancreas.com

Chair: Núria Malats, MD, MPH, PhD

4 /20

Scientific scope: Pancreas cancer

The pancreas has two main jobs in the body:

1. To make enzymes that help digest (exocrine)

2. To make hormones (insulin and glucagon) thathelp control blood sugar levels (endocrine)

About 95% of pancreatic cancers begin in exocrine cells

PDQ®5 /20

WW Pancreas Cancer Burden: an ORPHAN disease

Region

Men Women

Incidence* Mortality* Incidence* Mortality*

World 4.6 4.4 3.3 3.3

More

developed8.1 8.0 5.3 5.4

Less developed 2.1 2.6 2.1 2.0

*ASR(W): Patients per 100k inhabitants per year

6 /20

Death rates from pancreatic cancer are rising while rates for all other cancers continue to fall in Europe

Malvezzi M, Ann Oncol 2014

PANCREAS

Ferlay J, Acta Oncol 2016

More deaths from pancreatic cancerthan breast cancer in the EU by 2017

7 /20

Looking into the future: hoping to be wrong

8 /20

Defined as a “recalcitrant cancer” by the U.S. Congress leading to the implementation of a 5-year effective Pancreatic Cancer Research and

Education Act involving research for biomarkers of early detection.

9 /20

Pancreas cancer challenges

• Lack of awareness: Population, Patients and Physicians. Silent disease

• No 1ary prevention: complex aetiology

• No screening: lack of markers

• Late diagnosis and no efficient treatment

• Nihilism in patient management

• No survivors: Orphan disease

Ducreux M, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines fordiagnosis, treatment and follow-up. Ann Oncol. 2015 Sep.

• Low incidence underpowered studies

• High percentage of misdiagnosed patients misclassification

• Patients too sick to participate biases

• <20% of patients undergo surgery lack of tumor tissue

• Tumour embedded in a fibrotic mass sampling difficulties

• High levels of RNAses inappropriate sample

• Underfunded disease 10/20

EUPancreas Objectives

1. Integrate knowledge and experience in a multidisciplinary way “from cell to Society”

2. Foster collaborative research to improve ourunderstanding of pancreas cancer and its prevention, early diagnosis and treatment under the PersonalizedMedicine umbrella

3. Promote the application of uniform study tools andprotocols and their optimal use by researchers

4. Enhance the mobility and training of researchers

5. Disseminate the results produced to the broadersociety

www.eupancreas.com 11 /20

Scientific outputs related to

(WITHIN and BETWEEN WGs) networking

www.eupancreas.com 12 /20

Access to Personalised Medicine for Pancreas Cancer patientsApplication of an EU-index for barriers to PM

Angela BrandMarleen Jansen

Mastricht University, 2014

www.eupancreas.com 13 /20

Direct appeal to policymakers, legislators and regulators to encourage innovationand to broaden access to treatment, and to all stakeholders to work more closelytogether to reduce the burden of pancreatic cancer on patients and on society

www.eupancreas.com

14 /20

Capacity building related to

(WITHIN and BEYOND) COST networking

BM1006NGS

Fibre Laser

www.eupancreas.com 15 /20

http://www.pancreaticcancereurope.eu/

Supported by Celgene and Baxalta/Shire 16 /20

World Pancreas Cancer Day: 17 November 2016

http://www.worldpancreaticcancercoalition.org/

European Parliament BrusselsTuesday 15 November 2016

Hosted by Pavel Poc MEP and Alojz Peterle MEP

Event moderated by Jonathan Dimbleby

17 /20

Pancreatic Cancer Declaration

18 /20

Mapping Pancreas Cancer in Europe: The Clinical Registry

Pancreatic Cancer Europe

EUPancreas COST Action

EC-JRC/ENCR (Ispra)

19 /20

Carlo La Vecchia (VC)Irene Esposito (WG1)Kristel Van Steen (WG2)Stephan Hahn (WG3)Angela Brand (WG4)Filipe Silva (Diss)Ana Merino (CNIO-GH) 20 /20

Workshop 8 EU Action on Pancreas Cancer

September 2016

Chair:Elke Anklam, Director of EC JRC Directorate F – Health, Consumers and Reference Materials, Belgium

Speakers:Núria Malats, CNIO Madrid, SpainRicardo Baptista-Leite, Member of Parliament, PortugalMatthias Reumann, IBM Research Zurich, SwitzerlandLada Leyens, Swissmedic, SwitzerlandAngela Brand, Maastricht University, The Netherlands

Wake up Europe !!!

21 /20